Parse Biosciences and bit.bio announced a collaboration to build a transcription factor-driven cell identity map, covering both cell state and cell fate. The companies said they will combine bit.bio’s Opti-ox technology and Cell Foundry discovery platform with Parse’s scalable Evercode single-cell assay. The joint effort is designed to let researchers simultaneously test thousands of genetic variables and their corresponding cellular behaviors, with the partnership’s output expected to support predictive AI-driven therapy design and human cell manufacturing. bit.bio’s existing proprietary data will feed into the map-building process, and Parse said the goal is to create foundational datasets that establish causal links between genetic inputs and biological outputs. The deal reflects ongoing platform competition around generating large, interpretable datasets for model training in next-generation cell and gene workflows.